CymaBay Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Non-cash lease expense
Stock-based compensation expense
Accelerated vesting of stock-based compensation due to restructuring
Accretion of development financing liability
Write-off of deferred financing costs
Net (accretion) amortization of investments in marketable securities
Changes in assets and liabilities:
Interest receivable and other current assets
Prepaid research and development and other prepaid expenses
Prepaid expenses
Other prepaid expenses and current assets
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued restructuring charges
Accrued liabilities
Deferred collaboration revenue
Accrued research and development expenses
Other accrued liabilities

Net cash used in operating activities
Investing activities
Purchases of property and equipment
Purchases of marketable securities
Proceeds from maturities of marketable securities
Proceeds from sale of marketable securities
Net cash (used in) provided by investing activities

Financing activities
Proceeds from issuance of common stock pursuant to equity award plans
Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs
Proceeds from development financing, net of transaction costs
Net cash provided by financing activities
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents, and restricted cash at beginning of period
Cash, cash equivalents, and restricted cash at end of period
Supplemental disclosures:
Supplemental operating activities
Cash paid for amounts included in the measurement of lease liabilities
Operating lease right-of-use assets obtained in exchange for lease liabilities

Supplemental non-cash investing and financing activities
Right-of-use assets acquired in exchange for operating lease liabilities
Right-of-use assets acquired in exchange for finance lease liabilities
Accrued financing costs

Comments